GlassScriptPhysician profile
Asharul Usmani
NPI 1013140227
$8,612.55
in general payments reported to CMS, 2019-2025
38 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what 84% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $471 · 2021: $658 · 2022: $567 · 2023: $1,210 · 2024: $3,213 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,986 · Consulting Fee: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,986.02 |
| Consulting Fee | $2,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $3,714.84 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $1,028.51 | 2019-2025 | Tyvaso |
| Glaxosmithkline, LLC. | $898.36 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $431.98 | 2023-2025 | Winrevair |
| Insmed, INC. | $349.49 | 2021-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $336.21 | 2019-2025 | Fasenra, Tezspire, Andexxa |
| Grifols USA, LLC | $233.67 | 2019-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $185.14 | 2020-2025 | |
| Mylan Specialty L.P. | $147.44 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $126.94 | 2021-2025 | Dupixent |
| Inspire Medical Systems, INC. | $98.52 | 2024-2025 | Inspire |
| Amgen INC. | $94.46 | 2023-2025 | Tezspire |
| Ani Pharmaceuticals, INC. | $85.42 | 2023-2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $81.37 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.37 | 2019-2025 | Ofev, Jascayd |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $67.86 | 2025 | Ohtuvayre |
| Resmed Corp | $48.70 | 2024 | |
| Pfizer INC. | $42.79 | 2022 | |
| Inogen, INC. | $42.30 | 2022 | |
| Advanced Respiratory, INC | $41.43 | 2019-2020 | |
| Inari Medical, INC. | $40.96 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Genzyme Corporation | $40.72 | 2024-2025 | |
| Philips North America LLC | $40.33 | 2023-2024 | (Ak6) Vest Therapy |
| Gilead Sciences, INC. | $36.63 | 2022 | |
| Upsher-Smith Laboratories LLC | $36.63 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $31.34 | 2019 | |
| Ucb, INC. | $30.10 | 2023 | |
| Sk Life Science, INC. | $26.86 | 2024 | |
| Viatris Specialty LLC | $25.90 | 2025 | Yupelri |
| Lilly USA, LLC | $25.72 | 2025 | Zepbound |
| Cvrx, INC. | $22.09 | 2023 | Barostim Neo System |
| Takeda Pharmaceuticals U.S.A., INC. | $21.54 | 2020 | |
| Sunovion Pharmaceuticals INC. | $21.33 | 2019 | |
| Vifor Pharma, INC. | $20.77 | 2024 | Zemaira |
| Fisher & Paykel Healthcare INC | $18.19 | 2024 | Fisher & Paykel Healthcare |
| Circassia INC. | $14.31 | 2020 | |
| Sandoz INC. | $13.52 | 2024 | Treprostinil |
| La Jolla Pharmaceutical Company | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asharul Usmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.